CABONE

NCT02243605 📎

Regimen

Experimental
Cabozantinib 60 mg/d
Control
None (single-arm, 6-month non-progression + ORR co-primary)

Population

Advanced/metastatic osteosarcoma (n=45) or Ewing sarcoma (n=45) after >=1 prior therapy

Key finding

Cabozantinib active in both osteo and Ewing relapse, with actual RECIST responses (unlike regorafenib). Ewing ORR of 26% is one of the highest ever reported in relapsed Ewing. Tolerability issues typical of cabo.

Source: PMID 32078813

Timeline

    Guideline citations

    • NCCN BONE (p.32)